nach oben

International Journal of Hematology

Erschienen in:

19.02.2016 | Progress in Hematology

Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology

verfasst von: Hoon Kook, Nack-Gyun Chung, Hyoung Jin Kang, Ho Joon Im

Erschienen in: International Journal of Hematology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The treatment of choice for aplastic anemia (AA) in children has been HLA-matched family donor (MFD) hematopoietic stem cell transplantation (HSCT). For those lacking MFD, immunosuppressive therapy (IST) consisting of horse antithymocyte globulin (ATG) and cyclosporine has been successful. The choices of second and third line treatments are more complex and debatable, especially in the situation of unavailability of horse ATG. IST with rabbit ATG seems to be less effective. Recently, improved survival of non-MFD HSCTs has been documented. The outcome of matched or mismatched unrelated donor, umbilical cord blood, or haploidentical family donor transplantations will be discussed in AA children after IST failure. Experimental approaches of upfront HSCT using non-MFDs will be briefly touched. In this review, a treatment guideline for children with AA from the Korean Society of Pediatric Hematology Oncology will be presented along with a brief review of literature on current clinical practices in Korea.

Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509–19.CrossRefPubMedPubMedCentral

Mary JY, Baumelou E, Guiguet M, the French Cooperative Group for Epidemiological Study of Aplastic Anemia. Epidemiology of aplastic anemia in France: a prospective multicenter study. Blood. 1990;75(8):1646–53.PubMed

Montané E, Ibáñez L, Vidal X, Ballarín E, Puig R, García N, Catalan Group for Study of Agranulocytosis and Aplastic Anemia, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–23.CrossRefPubMed

Jeong DC, Chung NG, Kang HJ, Koo HH, Kook H, Kim SK, et al. Epidemiology and clinical long-term outcome of childhood aplastic anemia in Korea for 15 years: retrospective study of the Korean Society of Pediatric Hematology Oncology (KSPHO). J Ped Hematol Onocol. 2011;33(3):172–8.CrossRef

Marsh JC, Gordon-Smith EC. Insights into the autoimmune nature of aplastic anaemia. Lancet. 2004;364(9431):308–9.CrossRefPubMed

Dufour C, Pillon M, Sociè G, Rovò A, Carraro E, Bacigalupo A, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and pediatric disease working parties of the European group blood and bone marrow transplant. Br J Haematol. 2015;169(4):565–73.CrossRefPubMed

Yoshida N, Kobayashi R, Yabe H, Kosaka Y, Yagasaki H, Watanabe K, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. Haematologica. 2014;99(12):1784–91.CrossRefPubMedPubMedCentral

Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood. 1997;89(10):3890–1.PubMed

Resnick IB, Aker M, Shapira MY, Tsirigotis PD, Bitan M, Abdul-Hai A, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133(6):649–54.CrossRefPubMed

10.

Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation (EBMT-SAAWP), et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94(9):1312–5.CrossRefPubMedPubMedCentral

11.

Dietz AC, Lucchini G, Samarasinghe S, Pulsipher MA. Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia. Curr Opin Pediatr. 2016;28(1):3–11.CrossRefPubMed

12.

Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, British Society for Blood and Marrow Transplantation, Clinical Trials Committee, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49(1):42–8.CrossRef

13.

Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11–8.CrossRefPubMed

14.

Schrezenmeier H, Marin P, Raghavachar A, McCann S, Hows J, Gluckman E, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European bone marrow transplantation group SAA working party. Br J Haematol. 1993;85(2):371–7.CrossRefPubMed

15.

Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K, et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol. 2000;111(1):321–8.CrossRefPubMed

16.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–8.CrossRefPubMedPubMedCentral

17.

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. Blood. 2012;119(23):5391–6.CrossRefPubMed

18.

Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014;99(4):664–71.CrossRefPubMedPubMedCentral

19.

Barone A, Lucarelli A, Onofrillo D, Verzegnassi F, Bonanomi S, Cesaro S, et al. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP). Blood Cells Mol Dis. 2015;55(1):40–7.CrossRefPubMed

20.

Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622–7.CrossRefPubMed

21.

Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transpl. 2001;7(4):208–15.CrossRef

22.

Kojima S, Matsuyama T, Kato S, Kigasawa H, Kobayashi R, Kikuta A, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100(3):799–803.CrossRefPubMed

23.

Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S, Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transpl. 2005;36(11):947–50.CrossRef

24.

Kang HJ, Shin HY, Park JE, Chung NG, Cho B, Kim HK, Korean Society of Pediatric Hematology-Oncology, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: a phase II prospective multicenter study. Biol Blood Marrow Transpl. 2010;16(11):1582–8.CrossRef

25.

Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339–46.CrossRefPubMed

26.

Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, Japan Childhood Aplastic Anemia Study Group, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054–9.CrossRefPubMed

27.

Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK paediatric BMT working party, paediatric diseases working party and severe aplastic anaemia working party of EBMT. Br J Haematol. 2015;171(4):585–94.CrossRefPubMed

28.

Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, British Committee for Standards in Haematology, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43–70.CrossRefPubMed

29.

Yagasaki H, Takahashi Y, Kudo K, Ohashi H, Hama A, Yamamoto T, et al. Feasibility and results of bone marrow transplantation from an HLA-mismatched unrelated donor for children and young adults with acquired severe aplastic anemia. Int J Hematol. 2007;85(5):437–42.CrossRefPubMed

30.

Chung NG, Lee JW, Jang PS, Jeong DC, Cho B, Kim HK. Reduced dose cyclophosphamide, fludarabine and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia. Pediatr Transpl. 2013;17(4):387–93.CrossRef

31.

Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Japan Marrow Donor Program, et al. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood. 2011;118(11):3186–90.CrossRefPubMed

32.

Yoshimi A, Kojima S, Taniguchi S, Hara J, Matsui T, Takahashi Y, Japan Cord Blood Bank Network, et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transpl. 2008;14(9):1057–63.CrossRef

33.

Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V, et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transpl. 2011;17(1):78–85.CrossRef

34.

Park M, Lee YH, Kang H-R, Lee JW, Kang HJ, Park KD, et al. on behalf of the Korean Cord Blood Transplantation Working Party. Unrelated donor cord blood transplantation for non-malignant disorders in children and adolescents. Pediatr Transpl. 2014;18(2):221–9.

35.

Ruggeri A, de Latour RP, Rocha V, Larghero J, Robin M, Rodrigues CA, et al. Double cord blood transplantation in patients with high risk bone marrow failure syndromes. Br J Haematol. 2008;143(3):404–8.CrossRefPubMed

36.

Im HJ, Koh KN, Seo JJ. Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Korean J Pediatr. 2015;58(6):199–205.CrossRefPubMedPubMedCentral

37.

Sykes M, Preffer F, McAfee S, Saidman SL, Weymouth D, Andrews DM, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353(9166):1755–9.CrossRefPubMed

38.

Ciceri F, Lupo-Stanghellini MT, Korthof ET. Haploidentical transplantation in patients with acquired aplastic anemia. Bone Marrow Transpl. 2013;48(2):183–5.CrossRef

39.

Lang P, Schumm M, Greil J, Bader P, Klingebiel T, Muller I, et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin Padiatr. 2005;217(6):334–8.CrossRefPubMed

40.

Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14(6):641–50.CrossRef

41.

Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH, et al. A novel protocol for haploidentical hematopoietic SCT without in vitro T- cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transpl. 2012;47(12):1507–12.CrossRef

42.

Gao L, Li Y, Zhang Y, Chen X, Gao L, Zhang C, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transpl. 2014;49(4):519–24.CrossRef

43.

Esteves I, Bonfim C, Pasquini R, Funke V, Pereira NF, Rocha V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transpl. 2015;50(5):685–9.CrossRef

44.

Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of αβ + T and B cells in children with nonmalignant disorders. Blood. 2014;124(5):822–6.CrossRefPubMed

45.

Im HJ, Koh KN, Suh JK, Lee SW, Choi ES, Jang S, et al. Refinement of treatment strategies in ex vivo T-cell-depleted haploidentical SCT for pediatric patients. Bone Marrow Transpl. 2015;50(2):225–31.CrossRef

46.

Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transpl. 2013;19(5):754–9.CrossRef

47.

Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Wu CO, Young NS. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119(2):345–54.CrossRefPubMedPubMedCentral

48.

Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–9.CrossRefPubMedPubMedCentral

49.

Desmond R, Townsley DM, Dumitriu B, Olnes MJ, Scheinberg P, Bevans M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–25.CrossRefPubMedPubMedCentral

50.

Chuhjo T, Yamazaki H, Omine M, Nakao S. Danazol therapy for aplastic anemia refractory to immunosuppressive therapy. Am J Hematol. 2008;83(5):387–9.CrossRefPubMed

51.

Brodsky RA, Chen AR, Dorr D, Fuchs EJ, Huff CA, Luznik L, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010;115(11):2136–41.CrossRefPubMedPubMedCentral

52.

Scheinberg P, Townsley D, Dumitriu B, Scheinberg P, Weinstein B, Daphtary M, et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood. 2014;124(18):2820–3.CrossRefPubMedPubMedCentral

Titel: Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology
verfasst von: Hoon Kook
Nack-Gyun Chung
Hyoung Jin Kang
Ho Joon Im
Publikationsdatum: 19.02.2016
Verlag: Springer Japan
Erschienen in: International Journal of Hematology / Ausgabe 4/2016
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-016-1956-8

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Allogeneic hematopoietic stem cell transplantation for inherited bone marrow failure syndromes

The current perspective of low-grade myelodysplastic syndrome in children

Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling

TP53 mutations in older adults with acute myeloid leukemia

Evolution of myeloid leukemia in children with Down syndrome

Guest Editorial: Inherited bone marrow failure and myelodysplasia in children: how much do we know about pediatric diseases?

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie